Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Test cyp 25 mg-Estradiol cyp 5 mg/ml Recalled by Clinical Specialties Compounding Pharmacy Due to Lack of Assurance of Sterility: FDA inspection findings...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Clinical Specialties Compounding Pharmacy directly.
Affected Products
Test cyp 25 mg-Estradiol cyp 5 mg/ml, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907
Quantity: 4ml
Why Was This Recalled?
Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes
Where Was This Sold?
This product was distributed to 3 states: FL, GA, SC
About Clinical Specialties Compounding Pharmacy
Clinical Specialties Compounding Pharmacy has 50 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report